Search results for "Coronavirus"
COVID-19 and stroke, racial disparities; vaccine regulatory updates
Recent studies found that stroke risk in COVID-19 was highest in middle-aged patients, that higher death rates among Hispanic patients were linked to lower health care access, and that mild COVID-19 didn't lead to cardiac abnormalities. The FDA, NIH, and CDC updated their vaccine guidance.
https://acphospitalist.acponline.org/weekly/archives/2021/11/03/1.htm
3 Nov 2021
New research on steroids, tocilizumab, interferon beta-1a in COVID-19 inpatients
A 12-mg dose of dexamethasone didn't work any better than 6 mg in a trial of patients with severe hypoxemia, tocilizumab seemed to outperform steroids only in patients with the most inflammation, and interferon beta-1a did not help hospitalized patients on remdesivir.
https://acphospitalist.acponline.org/weekly/archives/2021/10/27/1.htm
27 Oct 2021
Heparin dosing for COVID-19 inpatients, expert perspectives on boosters
Two new trials offered some support for therapeutic anticoagulation in inpatients with elevated d-dimer levels. Antithrombotic therapy didn't prove helpful for outpatients with COVID-19. FDA advisors, an ACP/Annals forum, and recent research addressed vaccine effectiveness and boosters.
https://acphospitalist.acponline.org/weekly/archives/2021/10/20/1.htm
20 Oct 2021
Latest studies look at ECMO, prone positioning, antibodies, remdesivir
Mortality rates have risen among patients getting extracorporeal membrane oxygenation (ECMO) for COVID-19, one study found, while two others offered more evidence of the benefits of proning. Additional new research supported the use of monoclonal antibodies and remdesivir.
https://acphospitalist.acponline.org/weekly/archives/2021/10/06/1.htm
6 Oct 2021
CDC recommendations on COVID-19 vaccine boosters, new data on vaccine effectiveness
Several groups in the U.S., including health care workers, are now eligible to receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine at least six months after completing the initial two-dose series.
https://acphospitalist.acponline.org/weekly/archives/2021/09/29/1.htm
29 Sep 2021
Research, regulators consider booster dose of COVID-19 vaccine
In addition to booster shots, the latest COVID-19 research looked at vaccine effectiveness, remdesivir's effects, an early indicator of vaccine-induced immune thrombotic thrombocytopenia, and rates of follow-up after hospitalization.
https://acphospitalist.acponline.org/weekly/archives/2021/09/22/1.htm
22 Sep 2021
Rise in HAIs during the pandemic, guidance on monoclonal antibodies for COVID-19
A new study found significant growth in health care-associated infections (HAIs), especially central line-associated bloodstream infections, during 2020, and the NIH offered advice on prioritization when monoclonal antibodies can't be given to all eligible patients.
https://acphospitalist.acponline.org/weekly/archives/2021/09/15/1.htm
15 Sep 2021
New COVID-19 treatment recommendations, data on vaccines and delta variant
The NIH updated its recommendations on inpatient treatment to address medication availability, metoprolol showed promise in a small ICU study, and new research highlighted decreased vaccine effectiveness and increased illness severity with the delta variant.
https://acphospitalist.acponline.org/weekly/archives/2021/09/01/1.htm
1 Sep 2021
Avoiding SNFs and antibiotics, expecting long-term effects and boosters in COVID-19
One study showed how a new committee reduced discharges to skilled nursing facilities (SNFs) while another indicated that empiric antibiotics aren't necessary for ventilated COVID-19 patients. Officials announced plans for vaccine boosters, and convalescent plasma failed an outpatient trial.
https://acphospitalist.acponline.org/weekly/archives/2021/08/25/1.htm
25 Aug 2021
Dexamethasone use, pandemic cardiac arrests and HAIs, latest COVID-19 vaccine news
Recent studies looked at use of dexamethasone and rates of in-hospital cardiac arrest in COVID-19 patients, hospital-acquired infections (HAIs) during the pandemic, and vaccine-induced immune thrombocytopenia. Also, the FDA and new research supported a third vaccine dose for organ transplant patients.
https://acphospitalist.acponline.org/weekly/archives/2021/08/18/1.htm
18 Aug 2021